Document Detail

Angiotensin-converting enzyme inhibition to enhance vascular health--clinical and research models.
MedLine Citation:
PMID:  11497207     Owner:  NLM     Status:  MEDLINE    
Protection of the endothelium, the metabolically active inner lining of the vasculature, appears to be a key factor in maintaining cardiovascular (CV) health. The endothelium responds to hemodynamic and hormonal factors by secreting substances that maintain vascular homeostasis. Damage to the endothelium is an initial step in the development of CV disease. Angiotensin-converting enzyme (ACE) inhibitors, which block the formation of the vasoconstricting substance, angiotensin II, have proved to be a key therapy for hypertension and congestive heart failure. The activity of these agents in enhancing vascular health appears to be a critical factor in their therapeutic effectiveness. Large-scale clinical trials over the past decade have shown that ACE inhibition is an effective therapeutic means of not only prolonging survival and reducing morbidity after acute myocardial infarction, but also reducing all-cause mortality and morbidity in patients at high risk for CV disease, including patients with diabetes. ACE is found in far greater amounts in tissue than in plasma. Studies indicate that ACE inhibitors act at the tissue level to provide long-term cardioprotective effects that include a reduction in the progression of atherosclerosis. An issue to resolve is how much ACE inhibition is needed at the tissue level to reverse or prevent further vascular damage.
G L Bakris
Related Documents :
6133647 - Beta-adrenoceptor blockade and myocardial infarction: when should treatment start and f...
22781467 - Very long-term clinical follow-up after fractional flow reserve-guided coronary revascu...
21603417 - Rate-dependent left bundle-branch block in a child with propionic aciduria.
22361397 - Coronary artery disease progression late after successful stent implantation.
1992027 - Myocardial uptake of carbon-11-acetate as an indirect estimate of regional myocardial b...
23290547 - Intracoronary enalaprilat to reduce microvascular damage during percutaneous coronary i...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of hypertension     Volume:  14     ISSN:  0895-7061     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  2001 Aug 
Date Detail:
Created Date:  2001-08-10     Completed Date:  2001-12-07     Revised Date:  2009-02-24    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  264S-269S     Citation Subset:  IM    
Department of Preventive Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / pharmacology*,  therapeutic use
Blood Pressure / drug effects
Cardiovascular Diseases / prevention & control*
Endothelium, Vascular / drug effects*
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making.
Next Document:  Ongoing trials of angiotensin-converting enzyme inhibition: what they can tell us.